ArticleJournal of the American Heart Association2021
Incidence, Predictors, and Mortality in Patients With Liver Cancer After Fontan Operation.
Article in Journal of the American Heart Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- A Meta-Analysis of Cumulative Incidence of Hepatocellular Carcinoma After the Fontan Operation.Digestive diseases and sciences · 2024Pooled it
- Noninvasive risk stratification of liver nodule development in Fontan-associated liver disease using liver stiffness measurement.Hepatology international · 2026Article
- Hepatocellular carcinoma in Fontan-associated liver disease: Incidence, risk stratification, and surveillance implications.Hepatology communications · 2026Article
- MRI-derived IVIM-modelled diffusion-weighted imaging does not predict clinical outcomes in fontan-associated liver disease: to monitor or not to monitor the liver?Frontiers in pediatrics · 2026Article
- Revisiting Hepatic Fibrosis Risk in Congenital Heart Disease: Insights from Non-Invasive Markers and Echocardiography.Children (Basel, Switzerland) · 2025Article
- Fontan-Associated Liver Disease.Seminars in liver disease · 2025Review
- Risk of malignancy in adult patients with congenital heart disease: a clinical practice review.Cardiovascular diagnosis and therapy · 2025Review
- Paraganglioma and phaeochromocytoma in adult Fontan patients.Journal of medical imaging and radiation oncology · 2025Article
- Thromboprophylaxis strategies for patients with a Fontan palliation: practice in the NHS.The British journal of cardiology · 2025Article
- Gut Dysbiosis in Patients With Fontan Circulation.Journal of the American Heart Association · 2024Article
- Hepatocellular carcinoma in survivors after Fontan operation: a case-control study.European heart journal · 2024Article
- Outcomes after cancer diagnosis in children and adult patients with congenital heart disease in Sweden: a registry-based cohort study.BMJ open · 2024Article
- Unique Pulmonary Hypertensive Vascular Diseases Associated with Heart and Lung Developmental Defects.Journal of cardiovascular development and disease · 2023Review
- Surgical treatment of hepatocellular carcinoma after Fontan operation: three case reports and review of the literature.Clinical journal of gastroenterology · 2023Review
- Abdominal lymphatic pathway in Fontan circulation using non-invasive magnetic resonance lymphangiography.Heart and vessels · 2023Article
- Fontan-associated liver disease: Diagnosis, surveillance, and management.Frontiers in pediatrics · 2023Review
- Combined hepatocellular carcinoma-cholangiocarcinoma in a patient with Fontan-associated liver disease.BMJ case reports · 2022Article
- Laparoscopic hysterectomy for endometrial cancer after the Fontan procedure: The first case report.International cancer conference journal · 2022Article
- Incidence, Predictors, and Mortality in Patients With Liver Cancer After Fontan Operation.Journal of the American Heart Association · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Liver cancer (LC) is a serious late complication after the Fontan operation. However, the incidence, predictors, and prognosis remain unknown. The purpose of our study was to determine these clinical characteristics. Methods and Results We assessed liver function in 339 consecutive patients who had undergone the Fontan procedure from 2005 to 2019. LC was histologically diagnosed in 10 patients after a median period of 2.9 years (range: 0.3-13.8; median age: 29.9 years [range: 14.4-41.5 years]; overall median post-Fontan procedure follow-up: 25.6 years [range: 13-32.1 years]), and the annual incidence was 0.89%. Over the entire post-Fontan follow-up period, the annual incidences of new-onset LC in the second, third, and fourth decades were 0.14%, 0.43%, and 8.83%, respectively. The patients with LC had longer follow-up periods, higher levels of AFP (α-fetoprotein), and higher values of liver fibrosis indices (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.